Login Register Cart 0
Generic placeholder image

Pharmaceutical Nanotechnology

Editor-in-Chief

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Cancer Fighting SiRNA-RRM2 Loaded Nanorobots

Author(s): Arjun Sharma, Pravir Kumar and Rashmi K. Ambasta*

Volume 8, Issue 2, 2020

Page: [79 - 90] Pages: 12

DOI: 10.2174/2211738508666200128120142

Price: $65

Abstract

Background: Silencing of several genes is critical for cancer therapy. These genes may be apoptotic gene, cell proliferation gene, DNA synthesis gene, etc. The two subunits of Ribonucleotide Reductase (RR), RRM1 and RRM2, are critical for DNA synthesis. Hence, targeting the blockage of DNA synthesis at tumor site can be a smart mode of cancer therapy. Specific targeting of blockage of RRM2 is done effectively by SiRNA. The drawbacks of siRNA delivery in the body include the poor uptake by all kinds of cells, questionable stability under physiological condition, non-target effect and ability to trigger the immune response. These obstacles may be overcome by target delivery of siRNA at the tumor site. This review presents a holistic overview regarding the role of RRM2 in controlling cancer progression. The nanoparticles are more effective due to specific characteristics like cell membrane penetration capacity, less toxicity, etc. RRM2 have been found to be elevated in different types of cancer and identified as the prognostic and predictive marker of the disease. Reductase RRM1 and RRM2 regulate the protein and gene expression of E2F, which is critical for protein expression and progression of cell cycle and cancer. The knockdown of RRM2 leads to apoptosis via Bcl2 in cancer. Both Bcl2 and E2F are critical in the progression of cancer, hence a gene that can affect both in regulating DNA replication is essential for cancer therapy.

Aim: The aim of the review is to identify the related gene whose silencing may inhibit cancer progression.

Conclusion: In this review, we illuminate the critical link between RRM-E2F, RRM-Bcl2, RRM-HDAC for the therapy of cancer. Altogether, this review presents an overview of all types of SiRNA targeted for cancer therapy with special emphasis on RRM2 for controlling the tumor progression.

Keywords: Bcl2, cancer therapy, E2F, nanoparticle, RRM1, RRM2, SiRNA.

« Previous
Graphical Abstract

[1]
Rahman MA, Amin AR, Wang D, et al. RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy. Clin Cancer Res 2013; 19(13): 3416-28.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-0073] [PMID: 23719266]
[2]
Zheng S, Wang X, Weng YH, et al. siRNA Knockdown of RRM2 effectively suppressed pancreatic tumor growth alone or synergistically with doxorubicin. Mol Ther Nucleic Acids 2018; 12: 805-16.
[http://dx.doi.org/10.1016/j.omtn.2018.08.003] [PMID: 30153565]
[3]
Lewis CS, Voelkel-Johnson C, Smith CD. Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640. Oncotarget 2016; 7(37): 60181-92.
[http://dx.doi.org/10.18632/oncotarget.11112] [PMID: 27517489]
[4]
Wang N, Zhan T, Ke T, et al. Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancer. Br J Cancer 2014; 110(4): 1034-44.
[http://dx.doi.org/10.1038/bjc.2013.817] [PMID: 24423925]
[5]
Workman CT, Mak HC, McCuine S, et al. A systems approach to mapping DNA damage response pathways. Science 2006; 312: 1054.
[6]
Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432(7014): 173-8.
[http://dx.doi.org/10.1038/nature03121] [PMID: 15538359]
[7]
Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009; 457(7228): 426-33.
[http://dx.doi.org/10.1038/nature07758] [PMID: 19158789]
[8]
Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464(7291): 1067-70.
[http://dx.doi.org/10.1038/nature08956] [PMID: 20305636]
[9]
Liang WH, Li N, Yuan ZQ, Qian XL, Wang ZH. DSCAM-AS1 promotes tumor growth of breast cancer by reducing miR-204-5p and up-regulating RRM2. Mol Carcinog 2019; 58(4): 461-73.
[PMID: 30457164]
[10]
Zhong Z, Cao Y, Yang S, Zhang S. Overexpression of RRM2 in gastric cancer cell promotes their invasiveness via AKT/NF-κB signaling pathway. Pharmazie 2016; 71(5): 280-4.
[PMID: 27348973]
[11]
Li J, Pang J, Liu Y, et al. Suppression of RRM2 inhibits cell proliferation, causes cell cycle arrest and promotes the apoptosis of human neuroblastoma cells and in human neuroblastoma RRM2 is suppressed following chemotherapy. Oncol Rep 2018; 40(1): 355-60.
[http://dx.doi.org/10.3892/or.2018.6420] [PMID: 29749541]
[12]
Lin YX, Wang Y, Blake S, et al. RNA Nanotechnology-mediated cancer immunotherapy. Theranostics 2020; 10(1): 281-99.
[http://dx.doi.org/10.7150/thno.35568] [PMID: 31903120]
[13]
Tijsterman M, Plasterk RH. Dicers at RISC; the mechanism of RNAi. Cell 2004; 117(1): 1-3.
[http://dx.doi.org/10.1016/S0092-8674(04)00293-4] [PMID: 15066275]
[14]
Lee YS, Nakahara K, Pham JW, et al. Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways. Cell 2004; 117(1): 69-81.
[http://dx.doi.org/10.1016/S0092-8674(04)00261-2] [PMID: 15066283]
[15]
Heidel JD, Yi-Ching J, Yen Y, et al. Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res 2007; 13: 2207.
[http://dx.doi.org/10.1158/1078-0432.CCR-06-2218]
[16]
Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ 2018; 25(1): 27-36.
[http://dx.doi.org/10.1038/cdd.2017.161]
[17]
Hofmann MH, Heinrich J, Radziwill G, Moelling K. A short hairpin DNA analogous to miR-125b inhibits C-Raf expression, proliferation, and survival of breast cancer cells. Mol Cancer Res 2009; 7(10): 1635-44.
[http://dx.doi.org/10.1158/1541-7786.MCR-09-0043] [PMID: 19825990]
[18]
Kundu AK, Iyer SV, Chandra S, Adhikari AS, Iwakuma T, Mandal TK. Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma. PLoS One 2017; 12(6) e0179168
[http://dx.doi.org/10.1371/journal.pone.0179168] [PMID: 28636657]
[19]
Liu XE, Sun XD. Inhibiting K-ras signaling reserves the epithelial-mesenchymal transition of pancreatic cancer cells and its mechanisms. Hepatogastroenterology 2013; 60(125): 1169-73.
[PMID: 23803380]
[20]
Koldehoff M, Zakrzewski JL, Beelen DW, Elmaagacli AH. Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells. Cancer Gene Ther 2013; 20(7): 421-7.
[http://dx.doi.org/10.1038/cgt.2013.31] [PMID: 23788109]
[21]
Zhu XS, Lin ZY, Du J, Cao GX, Liu G. BCR/ABL mRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia. Asian Pac J Cancer Prev 2014; 15(12): 4773-80.
[http://dx.doi.org/10.7314/APJCP.2014.15.12.4773] [PMID: 24998540]
[22]
Chen J, Sun X, Shao R, Xu Y, Gao J, Liang W. VEGF siRNA delivered by polycation liposome-encapsulated calcium phosphate nanoparticles for tumor angiogenesis inhibition in breast cancer. Int J Nanomedicine 2017; 12: 6075-88.
[http://dx.doi.org/10.2147/IJN.S142739] [PMID: 28860767]
[23]
Yhee JY, Song S, Lee SJ, et al. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance. J Control Release 2015; 198: 1-9.
[http://dx.doi.org/10.1016/j.jconrel.2014.11.019] [PMID: 25481438]
[24]
Han J, Gao B, Jin X, et al. Small interfering RNA-mediated downregulation of beta-catenin inhibits invasion and migration of colon cancer cells in vitro. Med Sci Monit 2012; 18(7): BR273-80.
[http://dx.doi.org/10.12659/MSM.883205] [PMID: 22739727]
[25]
Zhao LJ, Xu H, Qu JW, Zhao WZ, Zhao YB, Wang JH. Modulation of drug resistance in ovarian cancer cells by inhibition of protein kinase C-alpha (PKC-α) with small interference RNA (siRNA) agents. Asian Pac J Cancer Prev 2012; 13(8): 3631-6.
[http://dx.doi.org/10.7314/APJCP.2012.13.8.3631] [PMID: 23098446]
[26]
Cavalieri S, Morelli D, Martinetti A, et al. Clinical implications for pro-GRP in small cell lung cancer. A single center experience. Int J Biol Markers 2018; 33(1): 55-61.
[http://dx.doi.org/10.5301/ijbm.5000305] [PMID: 28967066]
[27]
Isaksson S, Jönsson P, Monsef N, et al. CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma. PLoS One 2017; 12(10) e0186284
[http://dx.doi.org/10.1371/journal.pone.0186284] [PMID: 29049328]
[28]
Spivey KA, Banyard J, Solis LM, et al. Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev 2010; 19(5): 1362-72.
[http://dx.doi.org/10.1158/1055-9965.EPI-09-1095] [PMID: 20447926]
[29]
Jeong J, Choi J, Kim W, et al. Inhibition of ezrin causes PKCα-mediated internalization of erbb2/HER2 tyrosine kinase in breast cancer cells. J Biol Chem 2019; 294(3): 887-901.
[30]
Nicolini A, Carpi A, Ferrari P, et al. An individual reference limit of the serum CEA-TPA-CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer. Cancer Manag Res 2018; 10: 6879-86.
[http://dx.doi.org/10.2147/CMAR.S177522] [PMID: 30588093]
[31]
Perrier A, Boelle PY, Chrétien Y, et al. An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies. PLoS One 2020; 15(1) e0227356
[http://dx.doi.org/10.1371/journal.pone.0227356] [PMID: 31910438]
[32]
Reyes-Ortega F, Delgado ÁV, Schneider EK, Checa Fernández BL, Iglesias GR. Magnetic nanoparticles coated with a thermosensitive polymer with hyperthermia properties. Polymers (Basel) 2017; 10(1) E10
[http://dx.doi.org/10.3390/polym10010010] [PMID: 30966044]
[33]
Wan X, Liu C, Lin Y, Fu J, Lu G, Lu Z. pH sensitive peptide functionalized nanoparticles for co-delivery of erlotinib and DAPT to restrict the progress of triple negative breast cancer. Drug Deliv 2019; 26(1): 470-80.
[http://dx.doi.org/10.1080/10717544.2019.1576801] [PMID: 30957572]
[34]
Blair CM, Walsh NM, Littman BH, Marcoux FW, Baillie GS. Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - C-Raf. BMC Cancer 2019; 19(1): 266.
[http://dx.doi.org/10.1186/s12885-019-5489-4] [PMID: 30909892]
[35]
Li N, Xie X, Hu Y, et al. Herceptin-conjugated liposomes co-loaded with doxorubicin and simvastatin in targeted prostate cancer therapy. Am J Transl Res 2019; 11(3): 1255-69.
[PMID: 30972160]
[36]
Yang C, Gao S, Dagnæs-Hansen F, Jakobsen M, Kjems J. Impact of PEG chain length on the physical properties and bioactivity of PEGylated chitosan/siRNA nanoparticles in vitro and in vivo. ACS Appl Mater Interfaces 2017; 9(14): 12203-16.
[http://dx.doi.org/10.1021/acsami.6b16556] [PMID: 28332829]
[37]
Zou Y, Zhou J, Xu B, Li W, Wang Z. Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma. OncoTargets Ther 2019; 12: 3267-75.
[http://dx.doi.org/10.2147/OTT.S196347] [PMID: 31118677]
[38]
Xie N, Yao Y, Wan L, Zhu T, Liu L, Yuan J. Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer. Exp Ther Med 2017; 14(1): 338-43.
[http://dx.doi.org/10.3892/etm.2017.4464] [PMID: 28672935]
[39]
Wang N, Li Y, Zhou J. Downregulation of ribonucleotide reductase subunits M2 induces apoptosis and G1 arrest of cervical cancer cells. Oncol Lett 2018; 15(3): 3719-25.
[http://dx.doi.org/10.3892/ol.2018.7806] [PMID: 29556274]
[40]
Andrews JM, Schmidt JA, Carson KR, Musiek AC, Mehta-Shah N, Payton JE. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma. EBioMedicine 2019; 46: 170-83.
[http://dx.doi.org/10.1016/j.ebiom.2019.07.053] [PMID: 31358475]
[41]
Wang Z, Song J, Milne TA, et al. Pro isomerization in MLL1 PHD3-bromo cassette connects H3K4me readout to CyP33 and HDAC-mediated repression. Cell 2010; 141(7): 1183-94.
[http://dx.doi.org/10.1016/j.cell.2010.05.016] [PMID: 20541251]
[42]
Zhao H, Zheng GH, Li GC, et al. Long noncoding RNA LINC00958 regulates cell sensitivity to radiotherapy through RRM2 by binding to microRNA-5095 in cervical cancer. J Cell Physiol 2019; 234(12): 23349-59.
[http://dx.doi.org/10.1002/jcp.28902] [PMID: 31169309]
[43]
Yang Z, Yu B, Zhu J, et al. A microfluidic method to synthesize transferrin-lipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia. Nanoscale 2014; 6(16): 9742-51.
[http://dx.doi.org/10.1039/C4NR01510J] [PMID: 25003978]
[44]
Rahman MA, Amin AR, Wang X, et al. Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. J Control Release 2012; 159(3): 384-92.
[http://dx.doi.org/10.1016/j.jconrel.2012.01.045] [PMID: 22342644]
[45]
Kolesar J, Huang W, Eickhoff J, et al. Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. Cancer Chemother Pharmacol 2009; 64(1): 79-86.
[http://dx.doi.org/10.1007/s00280-008-0845-0] [PMID: 18941749]
[46]
Bartlett DW, Davis ME. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol Bioeng 2008; 99(4): 975-85.
[http://dx.doi.org/10.1002/bit.21668] [PMID: 17929316]
[47]
Heidel JD, Yu Z, Liu JY, et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA 2007; 104(14): 5715-21.
[http://dx.doi.org/10.1073/pnas.0701458104] [PMID: 17379663]
[48]
Kong L, Wu Y, Alves CS, Shi X. Efficient delivery of therapeutic siRNA into glioblastoma cells using multifunctional dendrimer-entrapped gold nanoparticles. Nanomedicine (Lond) 2016; 11(23): 3103-15.
[http://dx.doi.org/10.2217/nnm-2016-0240] [PMID: 27809656]
[49]
Mutso M, Nikonov A, Pihlak A, et al. RNA interference-guided targeting of hepatitis c virus replication with antisense locked nucleic acid-based oligonucleotides containing 8-oxo-dG modifications. PLoS One 2015; 10(6) e0128686
[http://dx.doi.org/10.1371/journal.pone.0128686] [PMID: 26039055]
[50]
Cui J, Qin L, Zhang J, et al. Ex vivo pretreatment of human vessels with siRNA nanoparticles provides protein silencing in endothelial cells. Nat Commun 2017; 8(1): 191.
[http://dx.doi.org/10.1038/s41467-017-00297-x] [PMID: 28775323]

Rights & Permissions Print Cite
Article Metrics
22
3
1
© 2024 Bentham Science Publishers | Privacy Policy